Table 1 Demographic Characteristics of Patients by Randomization Status

From: A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose

Variable

Statistic

Study Arm 1 (MVA-BN + MVA-BN) (N = 16)

Study Arm 2 (MVA-BN + Ad26 + MVA-BN) (N = 15)

Study Arm 3 (Ad26 + MVA-BN + MVA-BN) (N = 17)

Study Arm 4 (Ad26 + Ad26) (N = 17)

All Participants (N = 65)

Age (Years)

Mean

25.3

27.8

30.3

27.5

27.8

 

Standard Deviation

5.1

6.0

5.5

5.6

5.7

 

Median

25

26

30

27

27

 

IQR

21.5–27

23–32

26–34

23–29

23–31

BMI (kg/m2)

Mean

23.6

24.6

25.6

24.9

24.7

 

Standard Deviation

3.5

4.6

4.6

4.2

4.2

 

Median

23.3

24.1

24.4

24.3

24.1

 

IQR

20.4–25.9

20.8–26.4

23.4–28.6

20.8–28.8

20.8–27.1

Variable

Characteristic

Study Arm 1 (MVA-BN + MVA-BN) (N = 16) n (%)

Study Arm 2 (MVA-BN + Ad26 + MVA-BN) (N = 15) n (%)

Study Arm 3 (Ad26 + MVA-BN + MVA-BN) (N = 17) n (%)

Study Arm 4 (Ad26 + Ad26) (N = 17) n (%)

All Participants (N = 65) n (%)

Sex

Male

5 (31.3)

9 (60.0)

10 (58.8)

7 (41.2)

31 (47.7)

 

Female

11 (68.8)

6 (40.0)

7 (41.2)

10 (58.8)

34 (52.3)

Ethnicity

Not Hispanic or Latino

13 (81.3)

14 (93.3)

15 (88.2)

15 (88.2)

57 (87.7)

 

Hispanic or Latino

3 (18.8)

1 (6.7)

2 (11.8)

2 (11.8)

8 (12.3)

Race

Asian

-

4 (26.7)

1 (5.9)

2 (11.8)

7 (10.8)

 

Black or African American

-

-

-

2 (11.8)

2 (3.1)

 

White

14 (87.5)

11 (73.3)

15 (88.2)

12 (70.6)

52 (80.0)

 

Multi-Racial

2 (12.5)

-

1 (5.9)

1 (5.9)

4 (6.2)

  1. N = Number of Participants in the Safety Population.